Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

Core Insights - Clearside Biomedical, Inc. has appointed Dr. Glenn C. Yiu to its Scientific Advisory Board, enhancing its expertise in retinal disease treatment and suprachoroidal delivery methods [1][2] - Dr. Yiu is recognized for his contributions to the research and application of new delivery techniques for retinal diseases, particularly in age-related macular degeneration (AMD) [2][3] - The company is advancing its CLS-AX program, which is in Phase 2b clinical testing for wet AMD, and aims to expand its pipeline of therapies utilizing its patented SCS Microinjector [4][5] Company Overview - Clearside Biomedical, Inc. specializes in innovative delivery of therapies to the back of the eye through the suprachoroidal space (SCS) [4] - The SCS Microinjector allows for a non-surgical, repeatable procedure for targeted delivery of therapies to treat sight-threatening eye diseases [4] - The company's first FDA-approved product, XIPERE®, is available in the U.S. and is designed for suprachoroidal use [4] Dr. Glenn C. Yiu's Background - Dr. Yiu is a Professor of Ophthalmology at UC Davis and a board-certified vitreoretinal surgeon with extensive experience in translational research focused on retinal diseases [2][3] - He has pioneered techniques such as CRISPR-based genome editing for wet AMD and microneedles for suprachoroidal gene delivery [2][3] - Dr. Yiu has received numerous accolades for his research contributions and serves on various editorial boards and committees in the field of ophthalmology [3]